JPM vs NEA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NEA exhibits strong operational health with a Piotroski F-Score of 7/9, yet it faces significant valuation and sustainability headwinds. The current price of $11.47 trades at a substantial premium to both the Graham Number ($8.62) and Intrinsic Value ($8.26). While the Price/Book ratio of 0.97 suggests fair value relative to assets, the unsustainable payout ratio of 307.50% indicates that dividends are likely being funded by capital or leverage rather than earnings. Technical trends are currently bearish, offsetting the fund's strong financial health score.
Compare Another Pair
Related Comparisons
JPM vs NEA: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen AMT-Free Quality Municipal Income Fund (NEA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.